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Abstract
Purpose—There is a persistent HIV epidemic among sexual and gender minority adolescents in 
the U.S. Oral pre-exposure prophylaxis (PrEP) is an efficacious prevention strategy, but not yet 
approved for minors. Minors’ access to biomedical HIV prevention technologies is impeded the 
ethical and legal complexities of consent to research participation. We explore autonomous 
consent and study experiences among minor and adult participants in Project PrEPare, a Phase II 
safety study of PrEP for HIV prevention.
Methods—Data for this mixed-methods descriptive study were collected via self-administered 
web-survey and in-depth telephone interviews in early 2016. Eligible participants were previously 
enrolled in Project PrEPare. We attempted to contact 191 participants; 74 were reached and 
expressed interest in participating, 58 enrolled.
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Results—Participants nearly universally felt well informed, understood the study, and freely 
volunteered with the clear understanding they could withdraw any time. All felt supported by 
study staff, but a small minority wished for more support during enrollment. Minors were more 
likely than adults to indicate a wish for more support in decision-making, and adults expressed 
higher satisfaction with their decision compared to minors. There was no association between 
elements of consent and Project PrEPare study outcomes.
Conclusion—Participants had an overwhelmingly positive experience in a Phase II safety study 
of PrEP for HIV prevention. Some minors wished for more support during the decision making 
process, but none consulted their parents about the decision. Our results support the inclusion of 
decisional supports in consent processes for adolescents, while also protecting their privacy.
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Youth are disproportionately affected by the U.S. HIV epidemic, accounting for an estimated 
22% of incident infections.[1] Young men who have sex with men (YMSM) are at especially 
high risk; approximately 80% of all incident infections among persons aged 13–24 occur in 
YMSM.[1] Pre-exposure prophylaxis (PrEP) with oral tenofovir-emtricitabine (TDF-FTC) is 
approved to reduce the risk of sexually acquired HIV-1 in adults.[2, 3] TDF-FTC is not yet 
approved for PrEP among adolescents younger than 18 years (minor adolescents, 
henceforth) due to lack of data on its safety, tolerability, and effectiveness in this population.
There is a well-described reluctance to include minors in biomedical HIV prevention 
research,[4, 5] because doing so presents ethical complexities.[6] In most biomedical 
research, minor adolescents fall into the category of human subjects whose diminished 
autonomy requires additional protections, the cornerstone of which is parental permission.
[7] However, involving parents in the consent process may force the disclosure of the 
adolescent’s sexual behavior or sexual orientation, which poses risk of social harms.[8] 
Investigators and institutional review boards (IRBs) must weigh risks of social harm due to 
disclosure against other risks and benefits of research participation.
The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) faced these 
ethical complexities directly in Project PrEPare, an open-label, single arm study of PrEP 
safety and adherence among YMSM and young transwomen.[9] Concerns about disclosure-
related vulnerabilities prompted study organizers to allow minors to self-consent; parental 
permission was not required for enrollment.[9] Project PrEPare was the first biomedical HIV 
prevention study in the U.S. that allowed minors to autonomously consent for enrollment, 
where such consent was consistent with local statutes.[9, 10]
Relatively little research examines the relationship between consent processes and the 
experiences of participants after trial entry.[11] This mixed methods study explores 
autonomous consent and study experiences among the adolescents and young adults who 
enrolled in Project PrEPare. We chose a mixed methods design for a more complete picture 
of the phenomena under study.[12] Our aims were to describe five elements of consent: 
being informed, understanding the research study, feeling supported, freely volunteering to 
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enroll, and feeling satisfied with the research experience. A secondary aim was to explore 
the relationship between age, elements of consent, and Project PrEPare study outcomes 
(seroconversion, adherence).
Methods
Parent Study, Project PrEPare
Project PrEPare was conducted in two phases. The first phase (ATN 110) enrolled adults 
aged 18–22 (N=200), and the second phase (ATN 113) enrolled minors aged 15–17 (N=79). 
Trial results for both protocols are reported elsewhere.[13, 14] Briefly, a majority of 
participants achieved protective drug levels in the first month on study, but adherence 
declined thereafter, with rather sharp decreases occurring at week 24. There were a total of 7 
seroconversions, which occurred among participants with undetectable or very low drug 
levels.
Study population
Participants were research subjects in Project PrEPare. They were assigned male sex at birth, 
and were ages 15 to 22 years, inclusive, when they enrolled in the parent study. A total of 
279 YMSM and young transwomen from 12 urban ATN sites (AMTUs) were initially 
considered eligible. AMTU study staff contacted eligible participants and informed them 
about our study.
Study Procedures
Quantitative web-based survey—All participants completed a web-based survey to 
capture demographic data as well as data about participant experiences in Project PrEPare. 
Likert-type questions about the consent process measured the extent to which the participant 
felt informed, felt supported during the decision making process, and participated 
voluntarily. For example: I am satisfied I was given the information I needed to enroll in the 
study; I would have liked to have a parent/guardian with me when I made the decision to 
enroll. We also evaluated participants’ current understanding of research principles, 
generally, and the purpose of Project PrEPare, specifically, in addition to their experiences of 
research benefits and harms.
In-depth interview—At the end of the survey, each participant was asked if s/he would be 
willing to participate in a follow up interview. Interested participants were contacted and 
interviewed by the first author. Interview questions were designed to elicit in-depth 
descriptions of consent processes and study experiences. [15] For example: How capable do 
you think you were of making the decision to join this study? Is there anything you know 
now that you wish you had known when you first joined the study?
Data collection and management
Data were collected from January–April, 2016. Responses were stored on a secure ATN 
server. Interviews were conducted over the phone or videoconference and audio-recorded 
with permission. Audio files were transcribed by a professional service. Transcripts were 
compared to audio files for accuracy.
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Data analyses
Quantitative data—Surveys were linked to the following measures from Project PrEPare: 
age at consent, adherence at week 4 (dried blood spot analyses indicative of at least 4 doses/
week), and seroconversion. Data were stripped of identifiers, cleaned, and stored in SPSS. 
We used descriptive statistics to generate summaries of participants’ experiences on study. 
We constructed two summary measures, one reflecting a desire for support from an adult 
while making the enrollment decision (2 items, alpha=0.73), and one reflecting satisfaction 
with decision-making (3 items, alpha=0.79). Due to skewed distributions, we used non-
parametric tests to examine age-based differences in study experiences.
Qualitative data—Four members of the research team reviewed the transcripts and 
interview notes, and collectively discussed their key themes. Together with the study aims, 
these themes were used to develop an initial set of codes. The transcripts were coded in 
nVivo software. The first author took primary responsibility for analysis, meeting regularly 
with three other team members to discuss the coding and data interpretation. [15]
Human Subjects
Study procedures were reviewed and approved by 11 IRBs (see acknowledgements).
Results
We enrolled 58 participants (Figure 1). Fourteen were minors at enrollment in Project 
PrEPare, and 44 were at least 18 years of age (“adults,” henceforth). The age, racial and 
ethnic composition, and seroconversion rate of our substudy sample and the Project PrEPare 
sample are similar. All 58 completed the survey, and 44 indicated willingness to be 
interviewed. We attempted to contact and schedule interviews with all 44 but the number of 
interviews was limited by time and budgetary constraints. We interviewed 25 participants. 
To protect their privacy, they are assigned a unique id (I [number]), below.
Time since enrollment in Project PrEPare ranged from 17–37 months (median 31), and time 
since completing the study ranged from 0–24 months (median: 10). Among participants in 
this sub-study, adherence at study week four was 66%; there were 2 seroconversions. Aside 
from age, there were no significant differences in the demographic characteristics (Table 1) 
of minors compared to young adults. More than two-thirds of participants were persons of 
color, and 30% were Hispanic or Latino. Slightly more than two-thirds received at least one 
type of financial aid in the their lifetime. The majority (90%) identified as male, and 
indicated their sexual orientation is “gay” or “queer” (81%).
Description of Participants’ Perceptions of Five Elements of Consent
Being Informed—All participants indicated they received the information needed to make 
the enrollment decision (Table 2). This was reflected in the debriefing interviews. When 
asked whether there was anything they know now that they wished they had known from the 
beginning, 22 of the 25 interviewees could not think of anything. Interviewees said they 
were well informed, and knew exactly what to expect:
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“I felt it was perfectly clear. The staff, they were very helpful and the computer 
[surveys] were very detailed and so I feel like I have a complete understanding of 
[the study].” I23, minor
Two interviewees identified information they would have liked to know, if it were available: 
how TDF-FTC would interact with other medications and supplements, and a summary of 
clinical trial data to date. The third indicated he was confused about the bone density scan 
when it was time to have that exam; he remembered being told about it, but could not recall 
why it was necessary.
Understanding the research study—Table 2 indicates the extent to which surveyed 
participants agreed with a series of statements about research principles. Broadly, their 
responses reflect the positive experiences they had on study. For instance, 93% of 
participants indicated agreement that “researchers always try to give each person in a study 
the care that best meets their individual needs.” Few (10%) indicated it was possible to 
receive no benefit from participation in the study.
The debriefing interviews provide further insight into the quantitative data. It was clear that 
all participants understood they were part of a research study. They understood the study 
goals, which, they described both generically:
“I would say the main point is to prepare you to protect yourself against the STDs 
that are spreading so widely, which is HIV.” I3, adult
and more precisely:
“They had never done a large scale study in young gay men and they wanted to 
because we’re the fastest growing demographic for increasing HIV rates…they 
wanted to see how gay men reacted and if they would actually take PrEP.” I2, 
minor
At enrollment, interviewees anticipated a variety of benefits, including: extra protection 
against HIV (n=11), learning more about HIV and safer sex (n=8), frequent testing for HIV 
and STI (n=5), trying PrEP for free (n=4), financial compensation (n=4), access to good 
medical care (n=2) and a caring group of adults (n=2), and doing something good for the 
community (n=2). They also understood potential risks, including: side effects of TDF-FTC 
(e.g. weight gain, GI upset) (n=8), bone density loss (n=7), renal toxicity (n=4), social 
stigma if discovered taking an HIV treatment medication (n=4), risk compensation (e.g. 
more openness to condomless sex) (n=3), and viral resistance to medication (n=1). Five 
interviewees thought there were no risks, and one said he did not think about the risks.
We also assessed understanding by asking how expectations of the study compared to what 
was experienced. The interviewees said the study was about as expected (n=11), or better 
(n=10).
“I thought that I was just going to be a subject with a number…and I would just be 
given this, and labeled, and do tests. And really, it was an empowering experience 
in a way…They set a safe, open space where I felt comfortable with myself, I felt 
proud of myself.“ I22, adult
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Feeling Supported—Most participants (95%) felt supported by study staff when they 
enrolled. Half spoke with someone other than study staff prior to enrollment. These 29 
participants talked with: a friend (83%), a sexual partner (48%), an adult relative (21%), an 
older friend (21%), a parent or guardian (17%), or a teacher (10%). Some participants (19%) 
indicated feeling alone in the decision making process. One minor participant indicated he 
would have liked to have his parent or guardian present during decision-making, and three 
non-minors indicated a neutral opinion on this (Table 2). Five participants (9%) would have 
liked an adult relative, other than a parent or guardian, present to make the enrollment 
decision; four of these were minors.
The debriefing interviews allowed exploration of participants’ perceptions of the need for 
support during enrollment, regardless of their age at enrollment. Fifteen interviewees (60%; 
including 2 minors) could not think of anyone they wished would have helped make the 
decision to enroll; for them, the decision was very personal, and one they felt competent to 
make:
“I was kind of cool with just me and the doctor. At that time, I also was not out 
about my identity, so it was kind of like I didn’t want to really talk about it.” I13, 
minor
Two interviewees (8%; both adults) said that it would have been nice to have support at the 
time of consent; one suggested a best friend and the other said possibly his parents. Other 
interviewees (n=5) focused less on support and more on persons they definitely would not 
want present – namely, parents:
“I don’t really want to discuss anything with my parents. My dad’s on his own 
agenda…I don’t have any contact with [my mother] at all. So I’m pretty much by 
myself.” I23, minor
All minor interviewees said they either would not have wanted their parents present at 
enrollment (n=4) or did not feel the need to inform them (n=1).
Mirroring the survey data, about half (n=13) of interviewees spoke with someone about the 
study before enrolling, most often friends (n=9), followed by partners (n=3), and siblings 
(n=1). None of the interviewees spoke with a parent or guardian prior to enrollment. Of note, 
all minors we interviewed eventually discussed participation with their parents. Two minors 
voluntarily disclosed to parents midway through the study, two disclosed when parents or 
guardians noticed them traveling frequently (n=2), and one was not sure about the disclosure 
context. None reported an adverse outcome to the disclosure, but parents’/guardians’ 
reactions were mixed. The two who voluntarily disclosed described generally positive 
experiences, for example:
“My mom didn’t really express any concerns with me doing it, more so it was like 
I’m proud that you’re partaking and staying safe.” (I13, minor)
Among the two whose parents questioned them after noticing travel, reactions were neutral 
(I7) or positive (I24):
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I7: “I told my mom about it because she was like “Why the [expletive] is there a 
cab outside for you?’ … She did some research on it. When I came home she told 
me what it was about and I was like ‘I know, mom.’”
Interviewer: “Did she have anything either positive or negative to say about it?”
I7: “No, not really. Since I can remember any decision that I’ve made has really 
been mine. She can always put in her input, but whatever I wanted to do with 
myself, that was on me.”
“They were kind of curious to know ‘Why were you heading out to [city in which 
clinic is located] a lot?’ and so I told them what’s going on and this is what I’m 
participating in. They were like, ‘Okay’… All they understood was it was a medical 
study. I’ve explained it to them, but they weren’t concerned or anything. I guess 
anything that’s good they would encourage it.” (I24, minor)
Interviewee 23 was living with his mother during the study period, and she became aware 
that he was taking the study drug:
Interviewer: “And what did your mom say when she found out?”
I23: “She didn’t really accept it. She didn’t deny me taking it.”
Interviewer: “Do you have any sense for what about it she didn’t accept?”
I23: “She’s really manipulative and controlling, so it was just because I got it by 
myself, without her permission. She was upset about that more than the social issue 
of it.”
Interviewee 23 experienced emotional and physical abuse from his parents over the course 
of his lifetime, but denied experiencing any harm due to disclosure to his parents. He does 
not have contact with either parent now.
Freely volunteering to participate—Participants felt enrollment was voluntary; 98% 
indicated the decision to enroll was entirely their choice, and one (I9) indicated this was 
somewhat true. Interviewee 9 enrolled in the study because his partner suggested it “as a 
way for us to not have his status be so much of an issue.” None endorsed the statement that 
they had enrolled even though they did not want to, and none indicated it would look bad to 
study staff if they did not enroll. One participant indicated it was “somewhat true” that he 
felt like he was talked into enrolling in the study. This participant (I12) reported during the 
interview that he enrolled after he learned that his partner had been having unsafe sex with 
others. The participant was encouraged to enroll by a participating friend.
To better understand the extent to which participants voluntarily enrolled and participated, 
we asked what they would have done if they felt uncomfortable participating, or wanted to 
withdraw. All 25 interviewees felt free to withdraw at any time, for any reason. For example:
“I think I would have just let them know I didn’t want to do it…I never felt pressure 
that I had to stay.” I2, minor
Three interviewees discontinued TDF-FTC: two due to side effects and one because of low 
perceived HIV risk.
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Feeling Satisfied with the Research Experience—All survey participants (100%) 
indicated satisfaction with their decision to participate. However, five indicated neutrality or 
disagreement that the decision was the best one for them personally, and three indicated 
neutrality or disagreement that the decision was consistent with personal values. Four of 
these five participants were interviewed. One (I7) was a minor who discontinued PrEP due 
to side effects; when asked about his overall research experience, he said that the main 
impact was “that I know that medication is out there and it’s being worked on every day. But 
that would be about it.” The other three were adults that reported no harms on study, and 
nothing about the study caused discomfort or distress. However, Interviewee 6 said that 
while study participation led to more information about PrEP and safer sex, there was little 
impact on his life because he was “never a really sexual person to begin with.” Interviewee 9 
enrolled in the study because his HIV-infected partner suggested it. He said he probably 
would not have enrolled if he were not in a serodiscordant relationship, but:
“I feel like looking back on it, at the time it was the right decision. I think now that 
I’m single and testing a lot it’s a good precautionary measure to have on top of 
condoms and everything else.” I9, adult
Interviewee 8 reflected similarly on the study:
“I think it’s only benefitted me in the long run now that I take PrEP every day. I’m 
happy I take it. I think overall, it was the right choice.”
We further explored satisfaction with the study experience by asking interviewees to reflect 
on how the study had affected their lives. The majority expressed a positive, quite specific 
impact:
“It just helped me build my character up to where I was more focused on my 
education, and my coursework, and my employment.” I4, adult
Some viewed study participation as broadly life-changing, and were disappointed by study 
completion:
“Making that specific decision [to participate] made a lifetime of change for me, 
and I’m very, very glad about that…it really triggered my mind and it really 
challenged me.” I15, adult
“I was kind of upset that it was over…I would definitely do it again if I had the 
chance.” I24, minor
Relationship between Age, Consent, and Study Outcomes
There were statistically significant differences between minors and adults on two measures 
of support – feeling alone in one’s decision-making, and preference for having a non-
parental adult present at the time of consent (Table 3). In both cases, minors were more 
likely than adults to answer affirmatively. Neither summary measure was predictive of 
seroconversion or drug adherence.
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Discussion
Project PrEPare was the first U.S. study to offer PrEP to minor adolescents and is one of two 
biomedical HIV prevention trials that allowed autonomous consent.[16] Participants nearly 
universally felt adequately informed and they understood the basic premise of the study. 
This is consistent with prior research showing that adolescents are capable of understanding 
the concepts of randomization and placebo, but may need extra time and interaction (e.g. 
reframing unclear concepts) during consent processes to reduce the potential for therapeutic 
misconception. [17]
Participants did not distinguish between individually-focused care compared to clinical care 
provided as part of a clinical trial, largely agreeing “researchers always try to give people the 
care that fits their individual needs.” In the context of a placebo-controlled trial of a new 
medication, this may have raised concerns for therapeutic misconception. However, Project 
PrEPare was a single arm open-label study of a medication with demonstrated effectiveness, 
so it is reasonable for participants to expect they were getting treatment. Additionally, 
participants received individualized sexual risk reduction counseling and intensive clinical 
surveillance, making agreement with a statement about individualization of care more 
reasonable. Interviews with participants indicated they felt very well cared for by study staff, 
and the testing and counseling they received was one of the major benefits of this study.
Participants freely volunteered with the clear understanding they could withdraw at any 
time. A requirement for permission from others – particularly parents – was seen as largely 
unnecessary and an almost certain barrier to research participation. Our findings add to data 
showing that for sexual and gender minority youth, disclosure risks often outweigh the 
potential benefits of participation.[18, 19]
Our findings do not suggest, however, that research decision-making should be a solitary 
process, for minors or adults. Although participants felt supported by study staff during the 
consent process, some expressed need for support from others during enrollment. This need 
for support may be age-related: the mean summary support score was significantly lower 
among minors compared to young adults. These findings underscore the importance of 
clarifying the distinction between a voluntary decision and an independent decision.
Gillies & Entwistle [11] argue that in health care contexts, honoring the principle of respect 
for autonomy has too often resulted in the conflation of a voluntary choice and an 
independent one, at the risk of isolating participants from decisional supports. Such isolation 
may lead to negative research experiences and adverse outcomes such as early withdrawal or 
poor protocol adherence.[11] Further research is needed to identify who should be formally 
involved in the research consent process for minors considering participation in a biomedical 
HIV prevention trial; while parents’ authorization is required by regulation and tradition, 
sexual and gender minority youth in our study and others [18, 19] indicate parental 
involvement is a potentially non-negotiable barrier to research participation, especially on 
stigmatized conditions like HIV and sexual health. Our team is currently studying the 
acceptability of autonomous consent, flexible consent (choice between parent/guardian or an 
ombudsman), and required parental permission, from the perspectives of behaviorally high-
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risk adolescents and parents of adolescents. The prospect of direct participant benefit, 
coupled with the broader public health benefits of new prevention technologies, suggests the 
need for new regulatory and ethical pathways to support minor adolescents’ participation 
biomedical prevention research.
Few studies examine the relationship between the elements of consent and study outcomes. 
We did not find a significant relationship between two elements of consent (support and 
satisfaction with decision) and major study outcomes. However, those results should be 
interpreted with caution for two reasons: the skewed distribution of our data prohibited 
construction of summary scales for three other elements of consent, and, our sample size 
may have lacked power to detect differences.
Limitations
There are several limitations to our study that readers should keep in mind. A limited 
number of AMTUs participated in our study, so experiences presented here may not be 
representative of all Project PrEPare participants. However, the demographic characteristics 
of our sample are largely similar to the entire group of Project PrEPare participants. 
Participants were not randomly sampled, creating the possibility of self-selection bias. We 
attempted to counter this by reassuring participants their data would be stripped of 
identifiers and analyzed in aggregate, and that the interviewer was unaffiliated with AMTUs. 
The interviewer emphasized all opinions and perspectives were valued, therefore 
interviewees could answer honestly. Finally, we asked participants to comment on 
procedures and experiences that began as much as 37 months prior, raising the possibility of 
recall bias. However, we asked questions about their broader impressions of the study and 
how well informed they felt overall, rather than asking them to recount the consent process 
in detail.
Conclusion
There is a persistent HIV epidemic among YMSM and transgender women in the U.S. New 
prevention approaches, like PrEP, may be key to resolving HIV disparities among these 
youth. Currently, minors’ access to new prevention methods is limited by a research 
infrastructure that presents barriers to their inclusion in the very safety studies necessary for 
access. Ending the epidemic among youth may require new approaches to biomedical 
prevention research consent that allows equitable access to potential research benefits and 
protection from research-related harms.
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Implications and Contribution
Adult HIV prevention interventions may not be effective for adolescents, but ethical and 
legal issues often prevent minors from participating in HIV research. Adolescents who 
joined an HIV prevention study without parent permission had a positive experience. 
Researchers may consider using decisional supports when parents are not involved in 
research.
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Figure 1. 
Recruitment and enrollment from parent study
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Table 1
Demographic Characteristics
Demographic Characteristics
N %
Age* 17,25 22 (20,24)
Race#
 White 18 35
 Black or African American 26 51
 American Indian 1 2
 Multiracial 6 12
Ethnicity
 Non-Hispanic or non-Latino 40 70
 Hispanic or Latino 17 30
Gender identity
 Male 52 90
 Female or transgender 3 5
 Genderqueer or androgynous 3 5
Sexual orientation^
Straight 1 2
Gay, queer, or same gender loving 47 81
Bisexual 5 9
Trade 1 2
Questioning 1 2
Down Low 2 4
Other
Types of financial aid received in lifetime
 None 17 29
 One type 19 33
 Two or more types 22 38
*
Range (col 1), median, IQR (col 2);
#Column totals <58 reflect missing responses;
^Question referred to how participant views himself or herself, not how s/he presents to others
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Table 3
Summary measures
Minors
Mean (SE)
Non-Minors
Mean (SE) p-value*
Support Scale (Alpha=0.73)
I would have liked to have a parent/guardian present with me to make the decision about enrolling 
in the study
4.2 (.26) 4.7 (.09) 0.048I would have liked to have an adult other than my parent/guardian present with me to make the 
decision about enrolling in the study
Satisfaction Scale (Alpha=0.79)
The decision I made was the best decision for me personally
4.1 (.18) 4.7 (.07) 0.001I am satisfied that my decision was consistent with my personal values
I am satisfied with my decision
*
Mann Whitney U test
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